
HARVEST ONE CANNABIS INC (HVT.CA) Fundamental Analysis & Valuation
TSX-V:HVT • CA41755P1053
Current stock price
0.03 CAD
-0.01 (-14.29%)
Last:
This HVT.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. HVT.CA Profitability Analysis
1.1 Basic Checks
- HVT had negative earnings in the past year.
1.2 Ratios
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -102.61% | ||
| ROE | N/A | ||
| ROIC | 16.15% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 19.08% | ||
| PM (TTM) | -161.5% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. HVT.CA Health Analysis
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so HVT is still creating some value.
- The number of shares outstanding for HVT has been increased compared to 1 year ago.
- The debt/assets ratio for HVT is higher compared to a year ago.
2.2 Solvency
- Based on the Altman-Z score of -17.08, we must say that HVT is in the distress zone and has some risk of bankruptcy.
- A Debt/Equity ratio of 0.30 indicates that HVT is not too dependend on debt financing.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.3 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -17.08 |
ROIC/WACC1.79
WACC9.03%
2.3 Liquidity
- HVT has a Current Ratio of 1.02. This is a normal value and indicates that HVT is financially healthy and should not expect problems in meeting its short term obligations.
- HVT has a Quick Ratio of 1.02. This is a bad value and indicates that HVT is not financially healthy enough and could expect problems in meeting its short term obligations.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.02 | ||
| Quick Ratio | 0.64 |
3. HVT.CA Growth Analysis
3.1 Past
- HVT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 88.44%, which is quite impressive.
- Looking at the last year, HVT shows a very negative growth in Revenue. The Revenue has decreased by -38.19% in the last year.
- The Revenue has been growing by 122.12% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)88.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.45%
Revenue 1Y (TTM)-38.19%
Revenue growth 3Y122.12%
Revenue growth 5YN/A
Sales Q2Q%15.39%
3.2 Future
- Based on estimates for the next years, HVT will show a decrease in Earnings Per Share. The EPS will decrease by -7.07% on average per year.
- HVT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 51.78% yearly.
EPS Next Y-14.64%
EPS Next 2Y-7.07%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year50.65%
Revenue Next 2Y51.78%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. HVT.CA Valuation Analysis
4.1 Price/Earnings Ratio
- HVT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year HVT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 2.14 |
4.3 Compensation for Growth
- A cheap valuation may be justified as HVT's earnings are expected to decrease with -7.07% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-7.07%
EPS Next 3YN/A
5. HVT.CA Dividend Analysis
5.1 Amount
- No dividends for HVT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
HVT.CA Fundamentals: All Metrics, Ratios and Statistics
TSX-V:HVT (9/9/2022, 7:00:00 PM)
0.03
-0.01 (-14.29%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Industry Strength32.03
Industry Growth45.52
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.35%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap7.58M
Revenue(TTM)8.39M
Net Income(TTM)-13.54M
Analysts37.5
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.9 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.38 | ||
| P/tB | N/A | ||
| EV/EBITDA | 2.14 |
EPS(TTM)-0.05
EYN/A
EPS(NY)-0.01
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.03
BVpS0.02
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -102.61% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | 16.15% | ||
| ROICexc | N/A | ||
| ROICexgc | 38.88% | ||
| OM | 19.08% | ||
| PM (TTM) | -161.5% | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.64
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.3 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.02 | ||
| Quick Ratio | 0.64 | ||
| Altman-Z | -17.08 |
F-Score5
WACC9.03%
ROIC/WACC1.79
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)88.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.45%
EPS Next Y-14.64%
EPS Next 2Y-7.07%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-38.19%
Revenue growth 3Y122.12%
Revenue growth 5YN/A
Sales Q2Q%15.39%
Revenue Next Year50.65%
Revenue Next 2Y51.78%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A
HARVEST ONE CANNABIS INC / HVT.CA Fundamental Analysis FAQ
What is the ChartMill fundamental rating of HARVEST ONE CANNABIS INC (HVT.CA) stock?
ChartMill assigns a fundamental rating of 2 / 10 to HVT.CA.
Can you provide the valuation status for HARVEST ONE CANNABIS INC?
ChartMill assigns a valuation rating of 2 / 10 to HARVEST ONE CANNABIS INC (HVT.CA). This can be considered as Overvalued.
Can you provide the profitability details for HARVEST ONE CANNABIS INC?
HARVEST ONE CANNABIS INC (HVT.CA) has a profitability rating of 2 / 10.
Can you provide the expected EPS growth for HVT stock?
The Earnings per Share (EPS) of HARVEST ONE CANNABIS INC (HVT.CA) is expected to decline by -14.64% in the next year.